Ferring Pharmaceuticals, Inc.
🇺🇸United States
A Phase 1b Proof-of-concept Trial Exploring the Effects of FE 999322 and FE 999324 in Adults With Mild to Moderate Ulcerative Colitis
Phase 1
Withdrawn
- Conditions
- Ulcerative Colitis
- Interventions
- First Posted Date
- 2024-02-15
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 90
- Registration Number
- NCT06260267
- Locations
- 🇺🇸
Ferring Investigational Site, Oklahoma City, Oklahoma, United States
A Randomised Trial Comparing the Ovarian Response of a Starting Dose of Either 10 Μg or 15 Μg Follitropin Delta (FE 999049) to a Starting Dose of Either 150 IU or 225 IU Follitropin Alfa (GONAL-F) in Conventional Regimens in China
- First Posted Date
- 2023-12-18
- Last Posted Date
- 2025-03-03
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 300
- Registration Number
- NCT06173869
- Locations
- 🇨🇳
Ferring Investigational Site, Tianjin, Tianjin, China
ADSTILADRIN Early Utilization and Outcomes in the Real World Setting in the United States
- First Posted Date
- 2023-09-07
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 400
- Registration Number
- NCT06026332
- Locations
- 🇺🇸
Ferring Investigational Site, Virginia Beach, Virginia, United States
🇺🇸Ferring Investigation Site, Dallas, Texas, United States
A Study to Evaluate the Effect of Carbetocin on the QT/QTc Interval in Healthy Subjects
Phase 1
Completed
- Conditions
- Postpartum Hemorrhage
- Interventions
- First Posted Date
- 2023-06-29
- Last Posted Date
- 2023-09-26
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 40
- Registration Number
- NCT05924321
- Locations
- 🇺🇸
Ferring Investigational Site, Tempe, Arizona, United States
REBYOTA™ Prospective Registry
Recruiting
- Conditions
- Recurrence of Clostridium Difficile Infection
- Interventions
- Drug: REBYOTA™
- First Posted Date
- 2023-04-28
- Last Posted Date
- 2025-02-14
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 200
- Registration Number
- NCT05835219
- Locations
- 🇺🇸
Ferring Investigational Site, Charlottesville, Virginia, United States
🇺🇸Ferrin Investigational Site, Atlanta, Georgia, United States
A Multi-center, Single-arm Trial Exploring the Safety and Clinical Effectiveness of RBX2660 Administered by Colonoscopy to Adults With Recurrent Clostridioides Difficile Infection
- First Posted Date
- 2023-04-26
- Last Posted Date
- 2025-01-23
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 41
- Registration Number
- NCT05831189
- Locations
- 🇺🇸
Ferring Investigational Site, Madison, Wisconsin, United States
Safety and Efficacy of FE 999326 Administered Intravesically to Japanese Subjects with High-grade, BCG Unresponsive, Non-muscle Invasive Bladder Cancer (NMIBC)
- First Posted Date
- 2023-01-30
- Last Posted Date
- 2025-02-13
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 25
- Registration Number
- NCT05704244
- Locations
- 🇯🇵
Ferring Investigational Site, Wakayama-shi, Wakayama, Japan
Clinical Research Study to Learn About the Effect and Safety of Different Doses of FE 999302 When Given as a Single Dose for Final Development of the Eggs After Ovarian Stimulation
- First Posted Date
- 2022-10-07
- Last Posted Date
- 2023-01-09
- Lead Sponsor
- Ferring Pharmaceuticals
- Registration Number
- NCT05571111
- Locations
- 🇪🇸
Ferring Investigational Site, Valencia, Spain
Trial to Assess the Pattern of Use of REKOVELLE® in Women Undergoing In Vitro Fertilisation (IVF) or Intracytoplasmic Sperm Injection (ICSI) Procedures in Routine Clinical Practice
- First Posted Date
- 2022-08-12
- Last Posted Date
- 2024-04-16
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 201
- Registration Number
- NCT05499052
- Locations
- 🇨🇭
Ferring Investigational Site, Basel, Switzerland
A Trial to Compare Efficacy and Safety of Follitropin Delta Versus Placebo (Inactive Treatment) in the Treatment of Men With Idiopathic Infertility (Unexplained Reduction of Semen Quality) (ADAM)
- First Posted Date
- 2022-06-03
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 4
- Registration Number
- NCT05403476
- Locations
- 🇸🇪
Ferring Investigational Site, Stockholm, Sweden
🇺🇸Ferring investigational site, Webster, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath